Lifemd, INC. 8-K Filing
Ticker: LFMDP · Form: 8-K · Filed: Nov 4, 2025 · CIK: 948320
| Field | Detail |
|---|---|
| Company | Lifemd, INC. (LFMDP) |
| Form Type | 8-K |
| Filed Date | Nov 4, 2025 |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.01, $0.0001, $65.0 m, $24.0 million, $28.0 million |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Lifemd, INC. (ticker: LFMDP) to the SEC on Nov 4, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (ch registered Common Stock, par value $0.01 per share LFMD The Nasdaq Global Ma); $0.0001 (ve Perpetual Preferred Stock, par value $0.0001 per share LFMDP The Nasdaq Global M); $65.0 m (on an enterprise value of approximately $65.0 million, with 46.2% ($24.0 million) of th); $24.0 million (pproximately $65.0 million, with 46.2% ($24.0 million) of the aggregate purchase price paid a); $28.0 million (purchase price paid at close and 53.8% ($28.0 million) subject to future performance targets,).
How long is this filing?
Lifemd, INC.'s 8-K filing is 5 pages with approximately 1,538 words. Estimated reading time is 6 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 1,538 words · 6 min read · ~5 pages · Grade level 12.1 · Accepted 2025-11-04 14:48:10
Key Financial Figures
- $0.01 — ch registered Common Stock, par value $0.01 per share LFMD The Nasdaq Global Ma
- $0.0001 — ve Perpetual Preferred Stock, par value $0.0001 per share LFMDP The Nasdaq Global M
- $65.0 m — on an enterprise value of approximately $65.0 million, with 46.2% ($24.0 million) of th
- $24.0 million — pproximately $65.0 million, with 46.2% ($24.0 million) of the aggregate purchase price paid a
- $28.0 million — purchase price paid at close and 53.8% ($28.0 million) subject to future performance targets,
- $52.0 million — sideration paid to the Sellers of up to $52.0 million: 46.2% of the aggregate purchase pric
- $24.0 m — ent equal to the base purchase price of $24.0 million, subject to adjustments for net w
- $22.0 million — ed 91.6% of the base purchase price, or $22.0 million. A portion of the base purchase price w
- $26.0 m — nsists of a performance amount of up to $26.0 million, which the Sellers are entitled t
- $23.8 million — the Sellers, LifeMD would receive up to $23.8 million of the performance amount. 3.8% of th
- $2.0 m — ice consists of an activation amount of $2.0 million, which the Sellers are entitled t
- $1.8 million — the Sellers, LifeMD would receive up to $1.8 million of the activation amount. The executi
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex10-1.htm (EX-10.1) — 692KB
- ex99-1.htm (EX-99.1) — 19KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-25-020713.txt ( ) — 1104KB
- lfmd-20251104.xsd (EX-101.SCH) — 4KB
- lfmd-20251104_def.xml (EX-101.DEF) — 26KB
- lfmd-20251104_lab.xml (EX-101.LAB) — 36KB
- lfmd-20251104_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIFEMD, INC. Dated: November 4, 2025 By: /s/ Justin Schreiber Justin Schreiber Chairman and Chief Executive Officer